Dicot has identified several new patent opportunities

As a developing pharmaceutical company, Dicot follows a pronounced partnering strategy with a plan to out-license the company's drug candidate LIB-01 with data from clinical phase 2 studies. To maximize shareholder value from future out-licensing deals, the company works with a strong patent strategy to offer future licensees the longest possible market exclusivity via the company's patents.

Dicot's patent portfolio holds two granted patent families on key pharmaceutical markets, placing Dicot in a strong position and provides Dicot market exclusivity for LIB-01 until 2033.

Dicot now announces that ten new patent opportunities have been captured and documented. These new assets mean that Dicot has the opportunity to extend the patent protection of the company's drug candidate by 20 years after patent applications have been filed. That would mean extended patent protection until at least 2042.

To ensure maximum value from investments in patents, these assets are now controlled as trade secrets in order to be converted into patents at the right point of time. This ensures the longest possible patent life and value optimization.

"Dicot's IP portfolio is already a unique asset on the multi-billion pharmaceutical market for sexual dysfunction and we are committed to continue strengthening our IP portfolio and these new IP assets secure great long term value", says Göran Beijer, CEO at Dicot.